MLM Medical Labs leads in IVDR LDT Alzheimer’s biomarker testing with a validated Lumipulse® pTau217/Beta-Amyloid 1-42 plasma assay, enabling reliable, regulatory-compliant data to support global Alzheimer’s clinical trials.
Sponsors of global clinical trials don’t need another oversized, bureaucratic lab — they need a right-sized, science-first partner. Discover how MLM Medical Labs delivers proactive support, direct scientific access, and operational excellence across every phase of complex clinical trials worldwide.
What Global Trial Sponsors Need Now: A Proven, Right-Sized Central Lab Partner Read More »
Infectious disease trials demand speed, precision, and regional expertise. This article explores the top operational challenges sponsors face in Sub-Saharan Africa—and how MLM Medical Labs and Cytespace Africa Laboratories deliver a purpose-built, lab-integrated solution to accelerate timelines and improve data integrity.
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
When Inflammation Travels: Exploring the Link Between IBD and IPF Read More »
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
Reframing Fibrosis in Systemic Sclerosis: A Focus on Neutrophil–Macrophage Dynamics Read More »
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
CD4/CD8 Duplex Immunofluorescence : High-Resolution Immune Profiling from a Single Slide Read More »
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
Targeting the IRE1α-XBP1 Axis: A Novel Approach in ALI Treatment Read More »
A mid-sized biopharmaceutical company planning a global Phase II immuno-oncology trial in advanced solid tumors would face a critical operational challenge: ensuring consistent, high-quality PBMC processing across diverse geographies. PBMC-based immune monitoring is central to their biomarker strategy, but coordinating this across five continents introduces scientific and logistical risks.
This Applied Insights Brief outlines the likely challenges such a sponsor would encounter, how MLM Medical Labs would structure a tailored solution, and the measurable outcomes sponsors could expect by partnering with MLM.
Managing PBMC Complexity in Global Immuno-Oncology Trials Read More »
